

## HR 3513

### Prescription Drug Affordability Act of 2015

**Congress:** 114 (2015–2017, Ended)

**Chamber:** House

**Policy Area:** Health

**Introduced:** Sep 16, 2015

**Current Status:** Referred to the Subcommittee on Health.

**Latest Action:** Referred to the Subcommittee on Health. (Sep 18, 2015)

**Official Text:** <https://www.congress.gov/bill/114th-congress/house-bill/3513>

## Sponsor

**Name:** Rep. Cummings, Elijah E. [D-MD-7]

**Party:** Democratic • **State:** MD • **Chamber:** House

## Cosponsors (18 total)

Cosponsor	Party / State	Role	Date Joined
Del. Norton, Eleanor Holmes [D-DC-At Large]	D · DC		Sep 16, 2015
Rep. Ellison, Keith [D-MN-5]	D · MN		Sep 16, 2015
Rep. Sarbanes, John P. [D-MD-3]	D · MD		Sep 16, 2015
Rep. Schakowsky, Janice D. [D-IL-9]	D · IL		Sep 28, 2015
Rep. Cartwright, Matt [D-PA-17]	D · PA		Oct 8, 2015
Rep. Garamendi, John [D-CA-3]	D · CA		Nov 17, 2015
Rep. Jeffries, Hakeem S. [D-NY-8]	D · NY		Nov 17, 2015
Rep. Kaptur, Marcy [D-OH-9]	D · OH		Nov 17, 2015
Rep. Slaughter, Louise McIntosh [D-NY-25]	D · NY		Nov 17, 2015
Rep. Cohen, Steve [D-TN-9]	D · TN		Dec 11, 2015
Rep. DeSaulnier, Mark [D-CA-11]	D · CA		Dec 11, 2015
Rep. Huffman, Jared [D-CA-2]	D · CA		Jan 13, 2016
Rep. Titus, Dina [D-NV-1]	D · NV		Jan 13, 2016
Rep. Blumenauer, Earl [D-OR-3]	D · OR		Feb 4, 2016
Rep. Honda, Michael M. [D-CA-17]	D · CA		Feb 4, 2016
Rep. Bonamici, Suzanne [D-OR-1]	D · OR		Apr 29, 2016
Rep. Lowey, Nita M. [D-NY-17]	D · NY		Sep 26, 2016
Rep. Lujan Grisham, Michelle [D-NM-1]	D · NM		Nov 14, 2016

## Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Sep 18, 2015
Judiciary Committee	House	Referred To	Sep 16, 2015
Ways and Means Committee	House	Referred to	Sep 18, 2015

## Subjects & Policy Tags

### Policy Area:

Health

### Related Bills

Bill	Relationship	Last Action
114 S 2023	Identical bill	Sep 10, 2015: Read twice and referred to the Committee on Finance.
114 HR 3061	Related bill	Jul 20, 2015: Referred to the Subcommittee on Health.
114 HR 2391	Related bill	May 22, 2015: Referred to the Subcommittee on Health.
114 S 1364	Related bill	May 18, 2015: Read twice and referred to the Committee on Finance.
114 HR 2005	Related bill	May 13, 2015: Referred to the Subcommittee on Health.
114 S 1083	Related bill	Apr 23, 2015: Read twice and referred to the Committee on Finance.
114 S 31	Related bill	Jan 6, 2015: Read twice and referred to the Committee on Finance.

**Summary** (as of Sep 16, 2015)

### Prescription Drug Affordability Act of 2015

This bill amends titles XVIII (Medicare) and XIX (Medicaid) of the Social Security Act to modify provisions related to the affordability of prescription drugs under the Medicare and Medicaid programs. Specifically, the bill:

- requires the Centers for Medicare & Medicaid to negotiate lower prices on behalf of beneficiaries for drugs covered under Medicare Part D;
- accelerates closure of the Medicare Part D coverage gap known as the "donut hole," under which beneficiaries who have reached a certain level of yearly drug costs become fully responsible for any additional drug costs up to a certain limit;
- requires drug manufacturers to issue rebates for prescription drugs dispensed to eligible low-income individuals under Medicare or Medicaid; and
- expands the application of certain prescription drug rebate requirements under Medicaid to include rebates for generic drugs.

The bill also amends the Federal Food, Drug, and Cosmetic Act to: (1) allow the importation by individuals of prescription drugs from Canada and, potentially, other countries; and (2) establish certain conditions on the award of market exclusivity with respect to drugs. Specifically, a drug manufacturer's market exclusivity shall be terminated if the manufacturer commits, or fails to report, a drug-related violation such as misbranding, illegal marketing, or fraud.

In addition, the bill amends the Federal Trade Commission Act to: (1) establish restrictions on certain anticompetitive patent settlements known as "pay-for-delay" agreements, which effectively block generic drug competition; and (2) allow the Federal Trade Commission to initiate proceedings to enforce these restrictions against any parties to such a settlement.

The bill also requires drug manufacturers to produce and share annual reports containing specified information related to domestic and foreign sales.

## Actions Timeline

---

- **Sep 18, 2015:** Referred to the Subcommittee on Health.
- **Sep 16, 2015:** Introduced in House
- **Sep 16, 2015:** Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.